Faron Pharmaceuticals

0.48 EUR

-1.24 %

5,704 following
Corporate customer

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

-1.24 %
-14.21 %
-74.08 %
-76.10 %
-77.90 %
-80.27 %
-85.80 %
-87.38 %
-85.71 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
96.85M EUR
Turnover
124.48K EUR
P/E (adj.) (26e)
-4.62
EV/EBIT (adj.) (26e)
-5.32
P/B (26e)
82.78
EV/S (26e)
25,261.79
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
0.75 EUR
Updated
2026-03-11
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-03-12

Latest extensive report

Released: 2022-08-23

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Quite interesting, it just shows how challenging last year was in the M&A environment https://www.reuters.com/legal/transactional/big-pharma-ma-set-mega-year-patent-expiries-drive-deal-urgency-2026-05-01/ The value of acquisitions and mergers in Q1-Q3 /2026 was: 84 Billion In 2025...
5/7/2026, 10:23 AM
by Makkispekkis1
23
https://www.nature.com/articles/s41586-026-10452-4 Non-invasive profiling of the tumour microenvironment with spatial ecotypes A new study published in Nature is very interesting. It describes the tumor microenvironment (TME) as “spatial ecotypes.” They identified myeloid/SPP1/fibrotic...
5/6/2026, 8:37 PM
by poiju
23
Did you bring up the Matins ORR figure just because it supports your narrative? Wasn’t the purpose of Matins to investigate safety and appropriate dosage? Furthermore, there were several dosage levels involved, all the way down to 0.1 mg/kg, which even the paper considers likely ...
5/6/2026, 3:54 PM
by Makkispekkis1
21
EurekAlert! Mount Sinai study identifies new strategy to overcome immunotherapy... Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have identified a promising new strategy to overcome resistance to immunotherapy in colorectal cancer...
5/7/2026, 2:59 PM
by poiju
19
https://aacrjournals.org/bloodcancerdiscov/article/doi/10.1158/2643-3230.BCD-25-0393/784882/Understanding-the-Molecular-Mechanisms-Underlying Understanding the Molecular Mechanisms Underlying Anemia in Myelodysplastic Syndromes: From Erythropoiesis to New Therapeutic Approaches A...
4 hours ago
by poiju
15
So Eli Rannikko’s “TME dissertation” ties into that as a “common thread” very well!
5/7/2026, 4:05 AM
by Kulkuri
12
CD8 and Treg changes should not be interpreted too linearly as individual markers. Bex is not a direct T-cell activator, but an upstream myeloid checkpoint therapy that affects the entire tumor immune microenvironment through macrophages. It can reduce immunosuppression, help the...
5/6/2026, 7:50 PM
by poiju
12
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.